SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

NCT07374549 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Urothelial Carcinoma

Interventions

DRUG: SYS6002
DRUG: enfortumab vedotin

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.